Brief: Context Therapeutics Acquires Phase 1-Ready T Cell Engager CT-95
10/07/2024 12:46
July 10 (Reuters) - Context Therapeutics Inc CNTX.O :
* CONTEXT THERAPEUTICS ACQUIRES PHASE 1-READY T CELL ENGAGER
CT-95
* CONTEXT THERAPEUTICS - ACQUISITION EXPANDS CONTEXT
PIPELINE WITH
SECOND CLINICAL-STAGE T CELL ENGAGER FOR SOLID TUMORS
* CONTEXT THERAPEUTICS - CT-95 IS ON TRACK FOR PHASE 1
INITIATION
IN Q1 OF 2025
* CONTEXT THERAPEUTICS: INTEND TO FUND DEAL OF CT-95 AND
ADVANCEMENT THROUGH DOSE ESCALATION PORTION OF PHASE 1 CLINICAL
TRIAL WITH EXISTING CASH
Source text for Eikon: ID:nGNX6QTby2
Further company coverage: CNTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202